CR10253A - "inhibidores de pai-1 para tratamiento de afecciones musculares" - Google Patents

"inhibidores de pai-1 para tratamiento de afecciones musculares"

Info

Publication number
CR10253A
CR10253A CR10253A CR10253A CR10253A CR 10253 A CR10253 A CR 10253A CR 10253 A CR10253 A CR 10253A CR 10253 A CR10253 A CR 10253A CR 10253 A CR10253 A CR 10253A
Authority
CR
Costa Rica
Prior art keywords
muscle
pai
affections
inhibitors
treatment
Prior art date
Application number
CR10253A
Other languages
English (en)
Inventor
George Phillip Vlasuk
David Leroy Crandall
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10253A publication Critical patent/CR10253A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Esta invención proporciona, inter alia, métodos para tratar daño muscular, atrofia muscular progresiva, degeneración muscular, atrofia muscular o velocidad reducida de reparación muscular que comprende administrar una cantidad efectiva de un compuesto de un inhibidor PAI, como se proporciona aquí, a un mamífero en necesidad de este. La invención también proporciona, inter alia, composiciones farmacéuticas útiles para tratar daño muscular, atrofia muscular progresiva, degeneración muscular, atrofia muscular o velocidad reducida de reparación muscular que comprende un inhibidor PAI, como se proporciona aquí, y un recipiente farmaceuticamente aceptable.
CR10253A 2006-02-27 2008-08-27 "inhibidores de pai-1 para tratamiento de afecciones musculares" CR10253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77752106P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
CR10253A true CR10253A (es) 2008-11-18

Family

ID=38438022

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10253A CR10253A (es) 2006-02-27 2008-08-27 "inhibidores de pai-1 para tratamiento de afecciones musculares"

Country Status (20)

Country Link
US (1) US20070203220A1 (es)
EP (1) EP2010171A2 (es)
JP (1) JP2009528290A (es)
KR (1) KR20080108407A (es)
CN (1) CN101384256A (es)
AR (1) AR059629A1 (es)
AU (1) AU2007217363A1 (es)
BR (1) BRPI0710964A2 (es)
CA (1) CA2643731A1 (es)
CR (1) CR10253A (es)
EC (1) ECSP088699A (es)
GT (1) GT200800167A (es)
IL (1) IL192975A0 (es)
MX (1) MX2008011015A (es)
NO (1) NO20083438L (es)
PE (1) PE20071017A1 (es)
RU (1) RU2008128475A (es)
TW (1) TW200744585A (es)
WO (1) WO2007098278A2 (es)
ZA (1) ZA200807357B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176477A1 (en) * 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
GB0812192D0 (en) * 2008-07-03 2008-08-13 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN103724357B (zh) * 2012-10-11 2016-06-08 中国药科大学 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
WO2017073060A1 (ja) * 2015-10-29 2017-05-04 国立大学法人東北大学 コラーゲン産生抑制剤
US12011455B2 (en) * 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
EP4122489A4 (en) * 2020-03-24 2023-04-12 Talengen International Limited METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF
EP4140498A4 (en) * 2020-05-11 2023-11-01 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CA2509170A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569900B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60324183D1 (en) * 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
CA2509222A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
AU2005277137A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
WO2006023865A1 (en) * 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
CN101044127A (zh) * 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
BRPI0614340A2 (pt) * 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso

Also Published As

Publication number Publication date
AU2007217363A1 (en) 2007-08-30
EP2010171A2 (en) 2009-01-07
KR20080108407A (ko) 2008-12-15
WO2007098278A3 (en) 2008-03-20
JP2009528290A (ja) 2009-08-06
NO20083438L (no) 2008-10-31
TW200744585A (en) 2007-12-16
RU2008128475A (ru) 2010-04-10
ZA200807357B (en) 2009-08-26
AR059629A1 (es) 2008-04-16
US20070203220A1 (en) 2007-08-30
IL192975A0 (en) 2009-08-03
ECSP088699A (es) 2008-09-29
BRPI0710964A2 (pt) 2012-02-28
WO2007098278A2 (en) 2007-08-30
GT200800167A (es) 2009-01-15
MX2008011015A (es) 2008-11-14
PE20071017A1 (es) 2007-11-12
CA2643731A1 (en) 2007-08-30
CN101384256A (zh) 2009-03-11

Similar Documents

Publication Publication Date Title
CR10253A (es) "inhibidores de pai-1 para tratamiento de afecciones musculares"
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
NI200700320A (es) Inhibidores de la actividad akt
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
GT201200038A (es) Composicion para tratar la fibrosis quistica
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
AR060089A1 (es) Tratamiento del dolor
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
AR078082A1 (es) Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MA31706B1 (fr) Formulations galéniques de composés organiques
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2008011114A3 (en) Methionine aminopeptidase-2 inhibitors and methods of use thereof
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)